PRC200-SS

Last updated
PRC200-SS
PRC200 structure.png
Identifiers
  • (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.207.294 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C20H21NO
Molar mass 291.394 g·mol−1
3D model (JSmol)
  • O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2
  • InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1 X mark.svgN
  • Key:RSZGIFQDUIROGN-WOJBJXKFSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic. [1] [2]

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity, [3] precluding any further drug development.

References

  1. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID   18689611. S2CID   12635418.
  2. "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi: 10.1093/toxsci/kfr013 . PMID   21258088.